Advances in cosmeceutical nanotechnology for hyperpigmentation treatment
Source abstract
Abstract
Abstract Hyperpigmentation is a common and major skin problem that affects people of all skin types. Despite the availability of various depigmentation active ingredients for skin hyperpigmentation disorder, none of them are completely satisfactory due to their poor permeability through the skin layer and significant toxicity, thereby causing severe side effects such as irritative dermatitis, erythema, itching, and skin flaking. Nanotechnology plays an important role in advancing the cosmeceutical formulation by improving the solubility, stability, safety, loading efficiency, and dermal permeability of the active ingredients. The aim of this review is to offer a comprehensive discussion on the application of various nanomaterials in improving cosmeceutical formulations used to treat hyperpigmentation. Focus is placed on elucidating the advantages that nanotechnology can bring to some common hyperpigmentation active ingredients such as hydroquinone, arbutin, kojic acid, azelaic acid, and retinoic acid to improve their efficacy in treating hyperpigmentation. Lastly, a total of 44 reported patents and articles of depigmenting compounds encapsulated by nanoparticles were filed and analyzed. Overall, lipid nanoparticles were found to be the most widely used nanomaterial in treating hyperpigmentation. Graphical abstract
Source: crossref · Quality: baseline
Research context
OpenAlex topics: melanin and skin pigmentation · Skin Protection and Aging · Acne and Rosacea Treatments and Effects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Salvioni L, Morelli L, Ochoa E et al (2021) The emerging role of nanotechnology in skincare. Adv Colloid Interface Sci 293:102437. https://doi.org/10.1016/j.cis.2021.10243710.1016/j.cis.2021.102437 ↗
2. Ganceviciene R, Liakou AI, Theodoridis A et al (2012) Skin anti-aging strategies. Dermatoendocrinol 4:3. https://doi.org/10.4161/derm.2280410.4161/derm.22804 ↗
3. Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. Int J Nanomedicine 10:975–999. https://doi.org/10.2147/IJN.S6886110.2147/IJN.S68861 ↗
4. Chauhan A, Chauhan C (2021) Emerging trends of nanotechnology in beauty solutions: a review. Mater Today Proc. https://doi.org/10.1016/j.matpr.2021.04.37810.1016/j.matpr.2021.04.378 ↗
5. Khezri K, Saeedi M, Maleki Dizaj S (2018) Application of nanoparticles in percutaneous delivery of active ingredients in cosmetic preparations. Biomed Pharmacother 106:1499–1505. https://doi.org/10.1016/j.biopha.2018.07.08410.1016/j.biopha.2018.07.084 ↗
6. Lohani A, Verma A, Joshi H et al (2014) Nanotechnology-based cosmeceuticals. 2014.10.1155/2014/843687 ↗
7. Ahmad IZ, Ahmad A, Tabassum H, Kuddus M (2020) A cosmeceutical perspective of engineered nanoparticles. Handb. Nanomater. Manuf. Appl. 191–22310.1016/B978-0-12-821381-0.00008-9 ↗
8. Ourique AF, Pohlmann AR, Guterres SS, Beck RCR (2008) Tretinoin-loaded nanocapsules: preparation, physicochemical characterization, and photostability study. Int J Pharm 352:1–4. https://doi.org/10.1016/j.ijpharm.2007.12.03510.1016/j.ijpharm.2007.12.035 ↗
9. Nautiyal A, Wairkar S (2021) Management of hyperpigmentation: current treatments and emerging therapies. Pigment Cell Melanoma Res. https://doi.org/10.1111/pcmr.1298610.1111/pcmr.12986 ↗
10. Vashi NA, Kundu RV (2013) Facial hyperpigmentation: causes and treatment. Br J Dermatol 169:41–56. https://doi.org/10.1111/bjd.1253610.1111/bjd.12536 ↗
11. Slominski A, Tobin DJ, Shibahara S, Wortsman J (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84:1155–1228. https://doi.org/10.1152/physrev.00044.200310.1152/physrev.00044.2003 ↗
12. Chang TS (2009) An updated review of tyrosinase inhibitors. Int J Mol Sci 10:2440–2475. https://doi.org/10.3390/ijms1006244010.3390/ijms10062440 ↗
13. Zolghadri S, Bahrami A, Hassan Khan MT et al (2019) A comprehensive review on tyrosinase inhibitors. J Enzyme Inhib Med Chem 34:279–309. https://doi.org/10.1080/14756366.2018.154576710.1080/14756366.2018.1545767 ↗
14. Khan MTH (2012) Novel tyrosinase inhibitors from natural resources - their computational studies. Curr Med Chem 19:2262–227210.2174/092986712800229041 ↗
15. Jimbow K, Obata H, Pathak MA, Fitzpatrick TB (1974) Mechanism of depigmentation by hydroquinone. J Invest Dermatol 62:436–449. https://doi.org/10.1111/1523-1747.ep1270167910.1111/1523-1747.ep12701679 ↗
16. Nazzaro-Porro M, Passi S, Zina G, Breathnach AS (1990) The depigmenting effect of azelaic acid. Arch Dermatol 126:1649–165010.1001/archderm.1990.01670360117026 ↗
17. Maeda K, Fukuda M (1991) In vitro effectiveness of several whitening cosmetic components in human melanocytes. J Soc Cosmet Chem 42:361–368
18. Curto EV, Kwong C, Hermersdörfer H et al (1999) Inhibitors of mammalian melanocyte tyrosinase: In vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors. Biochem Pharmacol 57:663–672. https://doi.org/10.1016/S0006-2952(98)00340-210.1016/S0006-2952(98)00340-2 ↗
19. Kaul S, Gulati N, Verma D et al (2018) Role of nanotechnology in cosmeceuticals: a review of recent advances. J Pharm 2018:1–19. https://doi.org/10.1155/2018/342020410.1155/2018/3420204 ↗
20. Aziz ZAA, Mohd-Nasir H, Ahmad A et al (2019) Role of nanotechnology for design and development of cosmeceutical: application in makeup and skin care. Front Chem 7:1–15. https://doi.org/10.3389/fchem.2019.0073910.3389/fchem.2019.00739 ↗
21. Abu Hajleh MN, Abu-Huwaij R, Al-Samydai A et al (2021) The revolution of cosmeceuticals delivery by using nanotechnology: a narrative review of advantages and side effects. J Cosmet Dermatol 20:3818–3828. https://doi.org/10.1111/jocd.1444110.1111/jocd.14441 ↗
22. Purohit DK, Nandgude TD, Poddar SS (2016) Nano-lipid carriers for topical application: current scenario. Asian J Pharm 10:S1–S910.22377/ajp.v10i03.757 ↗
23. Müller RH, Radtke M, Wissing SA (2002) Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121–128. https://doi.org/10.1016/S0378-5173(02)00180-110.1016/S0378-5173(02)00180-1 ↗
24. Sakellari GI, Zafeiri I, Pawlik A et al (2021) Independent co-delivery of model actives with different degrees of hydrophilicity from oil-in-water and water-in-oil emulsions stabilised by solid lipid particles via a Pickering mechanism: a-proof-of-principle study. J Colloid Interface Sci 587:644–649. https://doi.org/10.1016/j.jcis.2020.11.02110.1016/j.jcis.2020.11.021 ↗
25. Zhang Z, Tsai PC, Ramezanli T, Michniak-Kohn BB (2013) Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology 5:205–218. https://doi.org/10.1002/wnan.121110.1002/wnan.1211 ↗
26. Fathi M, Zangabad PS, Majidi S et al (2017) Stimuli-responsive chitosan-based nanocarriers for cancer therapy. BioImpacts 7:269–277. https://doi.org/10.15171/bi.2017.3210.15171/bi.2017.32 ↗
27. Bhatia S (2016) Natural polymer drug delivery systems nanoparticles: nanoparticles, mammals and microbes 1:1–22510.1007/978-3-319-41129-3_1 ↗
28. Hiranphinyophat S, Otaka A, Asaumi Y et al (2021) Particle-stabilized oil-in-water emulsions as a platform for topical lipophilic drug delivery. Colloids Surfaces B Biointerfaces 197:111423. https://doi.org/10.1016/j.colsurfb.2020.11142310.1016/j.colsurfb.2020.111423 ↗
29. Huang X, Kobos RK, Xu G (2007) Hair coloring and cosmetic compositions comprising carbon nanotubes. United States Pat 2:1–29
30. Kaushik BK, Majumder MK (2015) Brajesh Kumar Kaushik Manoj Kumar Majumder
31. Li Z, Barnes JC, Bosoy A et al (2012) Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev 41:2590–2605. https://doi.org/10.1039/c1cs15246g10.1039/c1cs15246g ↗
32. Chen-Yang YW, Chen YT, Li CC et al (2011) Preparation of UV-filter encapsulated mesoporous silica with high sunscreen ability. Mater Lett 65:1060–1062. https://doi.org/10.1016/j.matlet.2010.12.03410.1016/j.matlet.2010.12.034 ↗
33. Li CC, Chen YT, Lin YT et al (2014) Mesoporous silica aerogel as a drug carrier for the enhancement of the sunscreen ability of benzophenone-3. Colloids Surf B Biointerfaces 115:191–196. https://doi.org/10.1016/j.colsurfb.2013.11.01110.1016/j.colsurfb.2013.11.011 ↗
34. Barel, André O., Marc Paye, and Howard I. Maibach eds (2014) Handbook of cosmetic science and technology, 4th ed. CRC Press 201410.1201/b16716 ↗
35. Ekambaram P, Sathali AH, Priyanka K (2012) Solid lipid nanoparticles- a review. Int J Appl Pharm 2:80–102
36. Gupta V, Mohapatra S, Mishra H et al (2022) Nanotechnology in cosmetics and cosmeceuticals — a review. 1–31
37. Kahraman E, Güngör S, Özsoy Y (2017) Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery. Ther Deliv 8:967–985. https://doi.org/10.4155/tde-2017-007510.4155/tde-2017-0075 ↗
38. Chandana KV, Vishal Gupta N, Kanna S (2019) Nanostructured lipid carriers: the frontiers in drug delivery. Asian J Pharm Clin Res 12:8–12. https://doi.org/10.22159/ajpcr.2019.v12i7.3359510.22159/ajpcr.2019.v12i7.33595 ↗
39. Kumar N, Kumar R (2014) Nano-based drug delivery and diagnostic systems. Nanotechnol. Nanomater. Treat. Life-threatening Dis. 53–10710.1016/B978-0-323-26433-4.00002-6 ↗
40. Lasic DD (1998) Novel applications of liposomes. Trends Biotechnol 16:307–32110.1016/S0167-7799(98)01220-7 ↗
41. Maali A, Mosavian MTH (2013) Preparation and application of nanoemulsions in the last decade (2000–2010). J Dispers Sci Technol 34:92–105. https://doi.org/10.1080/01932691.2011.64849810.1080/01932691.2011.648498 ↗
42. Naseri N, Valizadeh H, Zakeri-Milani P (2015) Solid lipid nanoparticles and nanostructured lipid carriers: structure preparation and application. Adv Pharm Bull 5:305–31310.15171/apb.2015.043 ↗
43. Nvs M (2011) Niosomes: a novel drug delivery system. Int J Res Pharm Chem ijrpc 1:498–511
44. Sarkar R, Arora P, Kv G (2013) Cosmeceuticals for hyperpigmentation: What is available? J Cutan Aesthet Surg 6:410.4103/0974-2077.110089 ↗
45. Solano F, Briganti S, Picardo M, Ghanem G (2006) Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 19:550–571. https://doi.org/10.1111/j.1600-0749.2006.00334.x10.1111/j.1600-0749.2006.00334.x ↗
46. Briganti S, Camera E, Picardo M (2003) Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res 16:101–110. https://doi.org/10.1034/j.1600-0749.2003.00029.x10.1034/j.1600-0749.2003.00029.x ↗
47. Shankar K, Godse K, Aurangabadkar S et al (2014) Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb) 4:165–186. https://doi.org/10.1007/s13555-014-0064-z10.1007/s13555-014-0064-z ↗
48. Bandyopadhyay D (2009) Topical treatment of melasma. Indian J Dermatol 54:303–309. https://doi.org/10.4103/0019-5154.5760210.4103/0019-5154.57602 ↗
49. Del Rosso JQ (2017) Azelaic acid topical formulations: differentiation of 15% gel and 15% foam. J Clin Aesthet Dermatol 10:37–4010.11138/cderm/2017.5.1.037 ↗
50. Kim YJ, Uyama H (2005) Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. Cell Mol Life Sci CMLS 62(15):1707–1723. https://doi.org/10.1007/s00018-005-5054-y10.1007/s00018-005-5054-y ↗
51. Amer M, Metwalli M (1998) Topical hydroquinone in the treatment of some hyperpigmentary disorders. Int J Dermatol 37:449–45010.1046/j.1365-4362.1998.00499.x ↗
52. Ennes SBP, Paschoalick RC, Alchorne MMDA (2000) A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J Dermatolog Treat 11:173–179. https://doi.org/10.1080/0954663005051733310.1080/09546630050517333 ↗
53. Haddad AL, Matos LF, Brunstein F et al (2003) A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol 42:153–156. https://doi.org/10.1046/j.1365-4362.2003.01621.x10.1046/j.1365-4362.2003.01621.x ↗
54. Morag M, Nawrot J, Siatkowski I et al (2015) A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of β-arbutin, in selected skin hyperpigmentations. J Cosmet Dermatol 14:185–190. https://doi.org/10.1111/jocd.1214710.1111/jocd.12147 ↗
55. Baliña LM, Graupe K (1991) The Treatment of melasma 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 30:893–895. https://doi.org/10.1111/j.1365-4362.1991.tb04362.x10.1111/j.1365-4362.1991.tb04362.x ↗
56. Sarkar R, Bhalla M, Kanwar AJ (2002) A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology 205:249–25410.1159/000065851 ↗
57. Monteiro RC, Kishore BN, Bhat RM, Sukumar D, Martis J, Ganesh HK (2013) A comparative study of the efficacy of 4% hydroquinone vs 0.75% kojic acid cream in the treatment of facial melasma. Indian J Dermatol 58:157. https://doi.org/10.4103/0019-5154.10807010.4103/0019-5154.108070 ↗
58. Griffiths CEM, Finkel LJ, Ditre CM et al (1993) Topical tretinoin (retinoic acid) improved melasma. A vehicle-controlled, clinical trial. Br J Dermatol 129:415–421. https://doi.org/10.1111/j.1365-2133.1993.tb03169.x10.1111/j.1365-2133.1993.tb03169.x ↗
59. Kimbrough-Green CK (1994) Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol 130:72710.1001/archderm.1994.01690060057005 ↗
60. Ghanbarzadeh S, Hariri R, Kouhsoltani M et al (2015) Enhanced stability and dermal delivery of hydroquinone using solid lipid nanoparticles. Colloids Surf B Biointerfaces 136:1004–1010. https://doi.org/10.1016/j.colsurfb.2015.10.04110.1016/j.colsurfb.2015.10.041 ↗
61. Huang H, Belwal T, Liu S et al (2019) Novel multi-phase nano-emulsion preparation for co-loading hydrophilic arbutin and hydrophobic coumaric acid using hydrocolloids. Food Hydrocoll 93:92–101. https://doi.org/10.1016/j.foodhyd.2019.02.02310.1016/j.foodhyd.2019.02.023 ↗
62. Tomić I, Juretić M, Jug M et al (2019) Preparation of in situ hydrogels loaded with azelaic acid nanocrystals and their dermal application performance study. Int J Pharm 563:249–258. https://doi.org/10.1016/j.ijpharm.2019.04.01610.1016/j.ijpharm.2019.04.016 ↗
63. Khezri K, Saeedi M, Morteza-Semnani K et al (2021) A promising and effective platform for delivering hydrophilic depigmenting agents in the treatment of cutaneous hyperpigmentation: kojic acid nanostructured lipid carrier. Artif Cells, Nanomedicine Biotechnol 49:38–47. https://doi.org/10.1080/21691401.2020.186599310.1080/21691401.2020.1865993 ↗
64. Raza K, Singh B, Lohan S et al (2013) Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm 456:65–72. https://doi.org/10.1016/j.ijpharm.2013.08.01910.1016/j.ijpharm.2013.08.019 ↗
65. Papaspyrides CD, Protopapas SA (1988) E.s.r. approach on hydroquinone-melanin possible interaction. Int J Biol Macromol 10:62–63. https://doi.org/10.1016/0141-8130(88)90070-010.1016/0141-8130(88)90070-0 ↗
66. Boo YC (2021) Arbutin as a skin depigmenting agent with antimelanogenic and antioxidant properties. Antioxidants 10:1–22. https://doi.org/10.3390/antiox1007112910.3390/antiox10071129 ↗
67. Wu PS, Lin CH, Kuo YC, Lin CC (2017) Formulation and characterization of hydroquinone nanostructured lipid carriers by homogenization emulsification method. J Nanomater 2017:.https://doi.org/10.1155/2017/328269310.1155/2017/3282693 ↗
68. Taheri A, Mohammadi M (2015) The use of cellulose nanocrystals for potential application in topical delivery of hydroquinone. Chem Biol Drug Des 86:882–886. https://doi.org/10.1111/cbdd.1246610.1111/cbdd.12466 ↗
69. Seo DH, Jung JH, Lee JE et al (2012) Biotechnological production of arbutins (α- and β-arbutins), skin-lightening agents, and their derivatives. Appl Microbiol Biotechnol 95:1417–1425. https://doi.org/10.1007/s00253-012-4297-410.1007/s00253-012-4297-4 ↗
70. Chawla S, Delong MA, Visscher MO et al (2008) Mechanism of tyrosinase inhibition by deoxyarbutin and its second-generation derivatives. Br J Dermatol 159:1267–1274. https://doi.org/10.1111/j.1365-2133.2008.08864.x10.1111/j.1365-2133.2008.08864.x ↗
71. Migas P, Krauze-Baranowska M (2015) The significance of arbutin and its derivatives in therapy and cosmetics. Phytochem Lett 13:35–40. https://doi.org/10.1016/j.phytol.2015.05.01510.1016/j.phytol.2015.05.015 ↗
72. Aung NN, Ngawhirunpat T, Rojanarata T et al (2020) HPMC/PVP dissolving microneedles: a promising delivery platform to promote trans-epidermal delivery of alpha-arbutin for skin lightening. AAPS PharmSciTech 21:1–13. https://doi.org/10.1208/s12249-019-1599-110.1208/s12249-019-1599-1 ↗
73. Leelapornpisid P, Leesawat P, Natakarnkitkul S, Rattanapanadda P (2010) Application of chitosan for preparation of arbutin nanoparticles as skin whitening. J Met Mater Miner 20:101–105
74. Ayumi NS, Sahudin S, Hussain Z et al (2019) Polymeric nanoparticles for topical delivery of alpha and beta arbutin: preparation and characterization. Drug Deliv Transl Res 9:482–496. https://doi.org/10.1007/s13346-018-0508-610.1007/s13346-018-0508-6 ↗
75. Park JJ, Hwang SJ, Kang YS et al (2019) Synthesis of arbutin–gold nanoparticle complexes and their enhanced performance for whitening. Arch Pharm Res 42:977–989. https://doi.org/10.1007/s12272-019-01164-710.1007/s12272-019-01164-7 ↗
76. Anirudhan TS, Nair SS, Sekhar VC (2017) Deposition of gold-cellulose hybrid nanofiller on a polyelectrolyte membrane constructed using guar gum and poly(vinyl alcohol) for transdermal drug delivery. J Memb Sci 539:344–35710.1016/j.memsci.2017.05.054 ↗
77. Dutta K, Das B, Orasugh JT et al (2018) Bio-derived cellulose nanofibril reinforced poly(N-isopropylacrylamide)-g-guar gum nanocomposite: an avant-garde biomaterial as a transdermal membrane. Polymer (Guildf) 135:85–102. https://doi.org/10.1016/j.polymer.2017.12.01510.1016/j.polymer.2017.12.015 ↗
78. Dutta K, Das B, Mondal D et al (2017) An: Ex situ approach to fabricating nanosilica reinforced polyacrylamide grafted guar gum nanocomposites as an efficient biomaterial for transdermal drug delivery application. New J Chem 41:9461–9471. https://doi.org/10.1039/c7nj01713h10.1039/c7nj01713h ↗
79. Bostanudin MF, Salam A, Mahmood A et al (2021) Formulation and in-vitro characterisation of cross-linked amphiphilic guar gum nanocarriers for percutaneous delivery of arbutin. J Pharm Sci 000:1–12. https://doi.org/10.1016/j.xphs.2021.08.01410.1016/j.xphs.2021.08.014 ↗
80. Kumar A, Rao R, Yadav P (2019) Azelaic acid: a promising agent for dermatological applications. Curr Drug ther 15:181–193
81. Sieber MA, Hegel JKE (2013) Azelaic acid: properties and mode of action. Skin Pharmacol Physiol 27:9–17. https://doi.org/10.1159/00035488810.1159/000354888 ↗
82. Malik DS, Kaur G (2018) Nanostructured gel for topical delivery of azelaic acid: designing, characterization, and in-vitro evaluation. J Drug Deliv Sci Technol 47:123–136. https://doi.org/10.1016/j.jddst.2018.07.00810.1016/j.jddst.2018.07.008 ↗
83. Li N, Wu X, Jia W et al (2012) Effect of ionization and vehicle on skin absorption and penetration of azelaic acid. Drug Dev Ind Pharm 38:985–99410.3109/03639045.2011.635376 ↗
84. Vidlářová L, Romero GB, Hanuš J et al (2016) Nanocrystals for dermal penetration enhancement - effect of concentration and underlying mechanisms using curcumin as model. Eur J Pharm Biopharm 104:216–22510.1016/j.ejpb.2016.05.004 ↗
85. Malamatari M, Taylor KMG, Malamataris S et al (2018) Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today 23:534–54710.1016/j.drudis.2018.01.016 ↗
86. Jacobus Berlitz S, De Villa D, Maschmann Inácio LA et al (2019) Azelaic acid-loaded nanoemulsion with hyaluronic acid–a new strategy to treat hyperpigmentary skin disorders. Drug Dev Ind Pharm 45:642–650. https://doi.org/10.1080/03639045.2019.156903210.1080/03639045.2019.1569032 ↗
87. Atrux-Tallau N, Lasselin J, Han SH et al (2014) Quantitative analysis of ligand effects on bioefficacy of nanoemulsion encapsulating depigmenting active. Colloids Surf B Biointerfaces 122:390–395. https://doi.org/10.1016/j.colsurfb.2014.07.02110.1016/j.colsurfb.2014.07.021 ↗
88. Kumari S, Pandita D, Poonia N, Lather V (2015) Nanostructured lipid carriers for topical delivery of an anti-acne drug: characterization and ex vivo evaluation. Pharm Nanotechnol 3:122–133. https://doi.org/10.2174/22117385030215111612475710.2174/221173850302151116124757 ↗
89. Lajis AFB, Hamid M, Ariff AB (2012) Depigmenting effect of kojic acid esters in hyperpigmented B16F1 melanoma cells. J Biomed Biotechnol 2012:.https://doi.org/10.1155/2012/95245210.1155/2012/952452 ↗
90. Gust PJ, Luke JD (2016) Kojic acid. J Dermatol Nurses Assoc 8:338–34010.1097/JDN.0000000000000247 ↗
91. Yamaguchi Y, Brenner M, Hearing VJ (2007) The regulation of skin pigmentation. J Biol Chem 282:27557–27561. https://doi.org/10.1074/jbc.R70002620010.1074/jbc.R700026200 ↗
92. Burdock GA, Soni MG, Carabin IG (2001) Evaluation of health aspects of kojic acid in food. Regul Toxicol Pharmacol 33:80–10110.1006/rtph.2000.1442 ↗
93. Wei CI, Huang TS, Fernando SY, Chung KT (1991) Mutagenicity studies of kojic acid. Toxicol Lett 59:213–22010.1016/0378-4274(91)90074-G ↗
94. Nakagawa M, Kawai K, Kawai K (1995) Contact allergy to kojic acid in skin care products. Contact Dermatitis 32:9–13. https://doi.org/10.1111/j.1600-0536.1995.tb00832.x10.1111/j.1600-0536.1995.tb00832.x ↗
95. Moto M, Mori T, Okamura M et al (2006) Absence of liver tumor-initiating activity of kojic acid in mice. Arch Toxicol 80:299–304. https://doi.org/10.1007/s00204-005-0034-410.1007/s00204-005-0034-4 ↗
96. Chusiri Y, Wongpoomchai R, Kakehashi A et al (2011) Non-genotoxic mode of action and possible threshold for hepatocarcinogenicity of kojic acid in F344 rats. Food Chem Toxicol 49:471–476. https://doi.org/10.1016/j.fct.2010.11.02710.1016/j.fct.2010.11.027 ↗
97. Nohynek GJ, Kirkland D, Marzin D et al (2004) An assessment of the genotoxicity and human health risk of topical use of kojic acid [5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one]. Food Chem Toxicol 42:93–10510.1016/j.fct.2003.08.008 ↗
98. Nawarak J, Huang-Liu R, Kao SH et al (2008) Proteomics analysis of kojic acid treated A375 human malignant melanoma cells. J Proteome Res 7:3737–374610.1021/pr7008737 ↗
99. Khezri K, Saeedi M, Morteza-Semnani K et al (2020) An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles. Artif Cells, Nanomedicine Biotechnol 48:841–853. https://doi.org/10.1080/21691401.2020.177027110.1080/21691401.2020.1770271 ↗
100. Yun GY, Yahya NA, Wahab RA, Hamid MA (2021) Formulation and characterization of a kinetically stable topical nanoemulsion containing the whitening agent kojic acid. Indones J Chem 21:400–410. https://doi.org/10.22146/ijc.5658710.22146/ijc.56587 ↗